Previous close | 229.89 |
Open | 233.61 |
Bid | 210.00 x 900 |
Ask | 259.98 x 800 |
Day's range | 232.38 - 238.38 |
52-week range | 161.65 - 275.00 |
Volume | |
Avg. volume | 533,343 |
Market cap | 12.026B |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | 25.32 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WILMINGTON, Mass., May 02, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
WILMINGTON, Mass., April 22, 2024--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
WILMINGTON, Mass., April 16, 2024--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.